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Specific Features of Non-small Cell Lung Cancer in
Women: A Retrospective Study of 1738 Cases Diagnosed
in Bas-Rhin between 1982 and 1997
Jacinthe Foegle´, MD,* Guy He´delin, PhD,* Marie-Paule Lebitasy, MD,† Ashok Purohit, MD,†
Michel Velten, MD, PhD,* and Elisabeth Quoix, MD†
Introduction: The literature suggests that lung cancer may repre-
sent a different disease in women compared with men and that
gender specificities have been reported mostly in clinical trials
patients.
Methods: We conducted a retrospective, population-based study of
a sample of 1738 patients diagnosed with a non-small cell lung
cancer (NSCLC) in the department of Bas-Rhin (northeastern
France) between 1982 and 1997. Our study aimed to describe
symptoms at presentation, stage, histological distribution, treatment
modalities, and survival, according to sex.
Results: Tobacco exposure differed significantly according to sex:
28.9% of women were nonsmokers versus 1.4% of the men. More
NSCLC were metastatic at diagnosis in women than in men (41.1%
versus 29.9%). Adenocarcinoma predominated in women (54.4%),
whereas squamous cell carcinoma predominated in men (65.9%).
Invasive procedures, such as transthoracic needle biopsy, contrib-
uted more frequently to histological diagnosis in women. Men and
women underwent the same procedures for disease staging, excepted
for the abdominal computed tomography scan, which was performed
more frequently in women. Treatment also differed: in resectable
disease, fewer pneumonectomies were performed in women; in
locally advanced disease, the mean doses of thoracic irradiation
were significantly lower in women (48.0 grays versus 55.5 grays); in
metastatic-stage disease, fewer women received platin-based che-
motherapy, but this difference was not significant. Sex was not a
significant prognostic factor in our study, contrary to most North
American studies, where women seem to have had better survival
rates.
Conclusions: This study emphasizes gender differences in smoking
exposure, presentation (stage, histological subtype), and diagnostic
and therapeutic management of NSCLC.
Key Words: Non-small cell lung cancer, Women, Gender, Sex,
Management, Survival.
(J Thorac Oncol. 2007;2: 466–474)
Lung cancer is the most common cancer worldwide, with1.35 million of new cases in 2002. It is also the leading
cause of cancer death, with 1.18 million deaths.1 Deaths
related to lung cancer overtook breast cancer deaths among
women in 1987 in North America.2 In France, it is now the
third-leading cause of cancer deaths among French women,
after breast and colorectal cancer.3 In 2000, about 28,000 new
cases of lung cancer were diagnosed in France: 23,152 in men
and 4591 in women.4
These increasing lung cancer mortality rates in women
contrast with the stabilization or even the decline observed in
men in industrialized countries,5,6 reflecting changes in the
smoking habits of women and men in various countries.
The literature suggests that lung cancer may represent a
somewhat different disease in women, and some gender
specificities have been reported.
If smoking is responsible for about 85% of lung cancer
cases in men, fewer than 75% are considered to be related to
smoking in women in Western countries.4 In Japan, figures
are different: two thirds of lung cancer cases in men are
attributable to smoking versus fewer than 15% in women.7
Thus, in at least 25% of lung cancer cases in women, other
risk factors are suspected, such as indoor pollution, diet, or
previous history of respiratory disease.
The distribution of lung cancer histologic subtypes
seems to be different between men and women: adenocarci-
noma predominates largely in women, whereas squamous
cell carcinoma remains the most frequent subtype in men in
France.8 Furthermore, female gender seems to be a favorable
prognostic factor in many publications.9,10
To characterize the specificities of NSCLC in women,
we conducted a retrospective, population-based study for a
16-year period on a sample of 1738 (of 5071 total) patients
diagnosed with a NSCLC in the department of Bas-Rhin
(France). Our objective was to describe symptoms at the time
of diagnosis, stage, histological subtype distribution, treat-
ment modalities, and survival, according to sex.
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PATIENTS AND METHODS
Patients
In a previous article, we have described trends in
management and survival without taking into account gender
specificities. Briefly, the list of patients with confirmed
NSCLC was obtained from the Bas-Rhin population-based
cancer registry. The Bas-Rhin is an administrative subdivi-
sion in northeastern France, with a population of roughly 1
million inhabitants.11 Between 1982 and 1997, 5071 new
cases of NSCLC were diagnosed. To determine whether the
5-year survival rates improved during the 16-year period, a
sample size of 490 patients was required in each of the four
periods.12 Thus, we randomly selected 2028 patients, whom
we stratified by year of diagnosis. This sample represented
40% of the whole NSCLC population.
The medical records of each patient were reviewed by
a physician. The following data were collected: age, sex,
smoking habits, date of diagnosis, histological subtype, in-
vestigations performed for diagnostic and staging purposes,
and disease extent. Patients’ participation in clinical trials
was documented. In situ carcinoma or a combination of
small-cell lung cancer and NSCLC were excluded from the
study. We did not attempt to assign stages retrospectively;
instead, we used the clinical gross classification assigned by
the physician at the time of diagnosis: resectable disease,
locally advanced unresectable disease, or metastatic disease.
The stage was classified as undetermined if the chart did not
report the local extent of the disease at diagnosis and if no
metastatic site was detected.
We also recorded the patient’s initial treatment: sur-
gery, radiotherapy, chemotherapy, palliative care. Chemo-
therapy was divided into older agents (mitomycin C, cyclo-
phosphamide, ifosfamide, 5FU, lomustine, and vindesine)
and more recent agents (vinorelbine, gemcitabine, irinotecan)
and was subdivided further into combinations with or without
platin salts (cisplatin or carboplatine).
Survival was estimated from the date of pathological
diagnosis. The end of follow-up was December 31, 2002.
Statistical Methods
Differences between proportions were assessed with
the Pearson 2 test or Fisher exact test when necessary.
Differences between the means of continuous variables were
evaluated with Student’s t test or, if the comparison involved
more than two groups, one-way analysis of variance.
All continuous variables were categorized for survival
analysis. We defined four consecutive periods covering 4
years each; age was separated into three classes (55 years,
56–70 years, and 70 years).
Our study covered a long period of time (16 years). To
take into account variations of survival for other diseases and
age-related mortality, we performed simple and multiple
regressive analysis of relative rather than crude survival13
with the RELSURV software package.14 Variables with a p
value of 0.20 or less in simple regressive analysis were
entered in the multiple regressive analysis. Sex and period
were forced into the model. The proportionality assump-
tion has been verified using interaction with time. Interac-
tions between variables were tested; none were statistically
significant.
The statistical analyses used the 8.2 SAS software
package (SAS Institute, Cary, NC).
RESULTS
Patients’ Characteristics
Among the 2028 patients, 93 did not meet the inclusion
criteria. We had to exclude 197 more patients from the 1935
eligible patients because of missing medical records. Thus,
the final sample included 1738 patients, 89.8% of the total
number (1935) of eligible patients. There were 1541 men
(88.7%) and 197 (11.3%) women. Sex ratio did not differ
between the 5071 patients of the overall population diagnosed
during the 16-year period and the sample of 1738 patients:
7.7 and 7.8, respectively.
The number of missing charts declined significantly
over time: from 15.5% in 1982–1985 to 9.5% in 1994–1997
(p  0.0008). Some differences were noted between the 197
excluded patients and the 1738 included patients. First, miss-
ing charts were more frequent in women (17.2% versus 9.2%
for men; p 0.0001). Second, the median age was 69.0 years
for patients with missing charts and 63.0 for included patients
(p  0.0001). Third, a significantly lower median survival
time was observed in excluded patients: 5.0 versus 10.5
months (p  0.00006). Median survival time did not differ
between women and men who were excluded from the study
(p  0.813).
The mean age at diagnosis did not differ between
women and men: 64.7 years and 63.2 years, respectively (p
0.069). Age 70 years was more frequent in women than in
men, although this difference did not reach statistical signif-
icance (p  0.058). The sex ratio declined regularly and
significantly from 10.6 in 1982–1985 to 6.7 in 1994–1997
(p  0.037; Figure 1). Women were more frequently never-
smokers than men (28.9% versus 1.4%). Among smokers,
74.5% had smoked more than 20 pack-years at diagnosis in
both sexes. Men had a more frequent history of chronic
obstructive pulmonary disease than women (45.8% versus
24.4%; p  0.0001). Men and women did not differ in their
history of cardiovascular diseases or of previous or simulta-
FIGURE 1. Number of men and women diagnosed with
non-small cell lung cancer (NSCLC) by periods of 4 years.
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neous cancer (diagnosed within 1 year of the lung cancer
occurrence). Patients’ characteristics are summarized in Ta-
ble 1.
Clinical Presentation
Symptoms at diagnosis did not differ significantly be-
tween men and women (Table 2). At diagnosis, 25.8% of the
men and 26.4% of the women had asymptomatic tumors. The
extent of the disease differed significantly between men and
women (p  0.0004); metastatic disease was more frequent
in women than in men: 41.1% versus 29.9%, respectively
(Table 2). Histological distribution differed significantly by
sex (p  0.0001). Adenocarcinomas other than bronchioloal-
veolar carcinomas (ADOBAC) and bronchioloalveolar carci-
nomas (BAC) were more frequent in women than in men.
Squamous cell carcinoma predominated in men (Table 2).
In women, histological diagnosis was less frequently
obtained by biopsy under fiberoscopy (42.1% versus 58.5%
for men; p  0.0001) and by bronchial brushing (17.3%
versus 25.0% for men; p  0.016). On the other hand,
transthoracic needle biopsy was performed, respectively, in
17.3% of the women and only 8.6% of the men (p 0.0001);
8.1 and 2.1%, respectively, for pleural tap (p  0.0001).
Histological distribution varied according to smoking
history in both sexes (men: p  0.011; women: p  0.002;
Table 3). In never-smoking women, ADOBAC predominated
(47.4% versus 21.1% for squamous cell carcinoma), whereas
squamous cell carcinoma slightly predominated in smoking
women (43.6% versus 37.6% for ADOBAC). When combin-
ing ADOBAC and BAC, there was still a slight excess of
squamous cell carcinoma in female smokers (43.6% versus
41.6%). In men, squamous cell carcinoma predominated in
smokers (66.3%). BAC proportion was higher in never-
smokers, in men (19.0%) as well as in women (21.1%), but
numbers are small (four in men and 12 in women). When
ADOBAC and BAC were combined, they became the most
frequent histological subtype in never-smoking males (47.6%
versus 42.9% for squamous cell carcinoma) and in never-
smoking females (68.5% versus 21.1% for squamous cell
carcinoma).
Histological distribution varied according to the period
(p  0.0003): ADOBAC in men increased from 18.5% in
1982–1985 to 26.2% in 1994–1997; in women, it increased
during the same time period from 33.3% to 54.7%.
Disease Extent Procedures
Men and women underwent the same tests at diagnosis,
excepted for the abdominal computed tomography scan,
which was performed in 21.8% of the women and in only
14.3% of the men (p  0.007; Table 4). The mean number of
procedures performed at diagnosis was similar: 2.2 tests were
performed at diagnosis in women, and 2.4 were performed in
men (p  0.197).
Among patients with disseminated disease, women had
more frequently pleural involvement (24.7% versus 11.3%;
p  0.001) and pulmonary metastases (35.8% versus 19.6%;
p  0.001) than men. For the other metastatic sites, no
differences were noted between groups. Bone was the most
frequent distant site (188 men [i.e., 40.9% of all men with
TABLE 1. Patients’ Characteristics and Medical History
Men Women
n % n % p
Age (yr) 0.058
55 343 22.3 41 20.8
55–70 789 51.2 88 44.7
70 409 26.5 68 34.5
Chronic obstructive pulmonary disease 0.0001
Yes 706 45.8 48 24.4
No 830 53.9 149 75.6
Unknown 5 0.3 0 0.0
Previous cancer 249 16.2 36 18.3 0.450
Cardiovascular disease 0.916
Yes 709 46.0 92 46.7
No 829 53.8 105 53.3
Unknown 3 0.2 0 0.0
Smoking history 0.0001
Smokers and former smokers 1421 92.2 101 51.3
Never-smokers 21 1.4 57 28.9
Unknown 99 6.4 39 19.8
Number of pack-years 0.528
10 18 1.3 1 1.0
10–20 89 6.3 10 9.9
20 1060 74.6 74 73.3
Unknown 254 17.9 16 15.8
TABLE 2. Clinical Presentation and Stage at Diagnosis
Men Women
n % n % p
Clinical signsa
Respiratory symptoms 729 47.3 83 42.1 0.170
Mediastinal or parietal
involvement symptoms
176 11.4 29 14.7 0.176
Metastatic symptoms 140 9.1 20 10.2 0.626
Paraneoplasic symptoms 34 2.2 4 2.0 0.999
Deterioration of general condition 342 22.2 47 23.9 0.598
Asymptomatic tumors 398 25.8 52 26.4 0.864
Stage 0.0004
Resectable 707 45.9 78 39.6
Locally advanced 286 18.6 26 13.2
Bilateral disease 38 2.5 0 0.0
Metastatic 460 29.9 81 41.1
Undetermined 50 3.2 12 6.1
Histological subtype 0.0001
Squamous cell 1016 65.9 62 31.5
Adenocarcinomas other than
bronchioloalveolar carcinomas
323 21.0 86 43.7
Bronchioloalveolar carcinomas 52 3.4 21 10.7
Large cell 137 8.9 24 12.2
Mixed 13 0.8 4 2.0
a The addition of the percentages exceeds 100% because several symptoms may be
associated.
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stage IV disease] and 31 women [i.e., 38.3%]). The following
most frequent sites were liver and brain, respectively, in 118
(25.7%) and 109 (23.7%) men and in 16 (19.8%) and 15
(18.5%) women.
Treatment
Seventeen patients were excluded from further analyses
because they died before diagnosis or because NSCLC was
discovered incidentally at autopsy.
Globally first-line treatment was similar in men and
women with resectable (p  0.647), locally advanced (p 
0.717), and metastatic disease (p  0.803) (Table 5). Never-
theless, some differences were noted within each category of
treatment.
In resectable disease, surgical procedures varied signif-
icantly according to gender (p  0.047). The proportion of
lobectomies was greater in women (72.6%) than in men
(59.9%), whereas more men underwent pneumonectomy
(30.1% versus 14.5%) in women. Bilobectomy represented
8.1% of the surgical procedures in women and 6.9% in men;
atypical resection (wedge resection of segmentectomy) was
performed in 4.8% of women and in 3.1% of men.
The mean doses of mediastinal tumor irradiation were
similar in both genders for resectable and metastatic disease:
respectively, 56.0 versus 55.6 grays (p  0.849) and 43.4
versus 41.9 grays (p  0.685). Nevertheless, it differed
significantly in locally advanced disease, with a mean dose of
48.0 grays in women versus 55.5 grays in men (p  0.016).
We could not describe possible sex differences regard-
ing chemotherapy in resectable and locally advanced disease,
because too few women underwent this therapy. For meta-
static disease, no sex-related difference was noted in the type
of chemotherapy used (p  0.355). Platin-based chemother-
apy with older agents was given to 50.6% of men and to
37.5% of women. Platin-based chemotherapy with modern
TABLE 3. Histological Distribution According to Sex and Smoking Habits
Men Women
Smokers and
Former Smokers Never-Smokers
Smokers and
Former Smokers Never-Smokers
Histological Subtype n % n % n % n %
Squamous cell 942 66.3 9 42.9 44 43.6 12 21.1
Adenocarcinoma (except bronchioloalveolar carcinoma) 297 20.9 6 28.6 38 37.6 27 47.4
Bronchioloalveolar carcinoma 44 3.1 4 19.0 4 4.0 12 21.1
Large cell 125 8.8 2 9.5 14 13.9 5 8.8
Mixed 13 0.9 0 0.0 1 1.0 1 1.8
TABLE 4. Diagnostic and Staging Procedures Performed at
Diagnosis According to Sex
Men Women
Procedures n % n % p
Thoracic CT scan 991 65.0 132 67.3 0.513
Bronchofiberoscopy 1490 97.3 186 95.4 0.145
Mediastinoscopy 14 0.9 3 1.6 0.429
Abdominal US 1375 91.4 172 89.6 0.414
Abdominal CT scan 216 14.3 42 21.8 0.007
Brain CT scan 790 52.4 102 52.8 0.911
Bone scan 743 49.4 90 47.1 0.553
Brain scan 78 5.2 5 2.6 0.120
Brain NMR 18 1.2 3 1.6 0.724
Thoracic NMR 29 1.9 4 2.1 0.783
Other 127 8.4 20 10.5 0.348
CT, computed tomography; US, ultrasound; NMR, nuclear magnetic resonance
imaging.
TABLE 5. First-line Treatment According to Sex
Men Women
First-Line Treatments n % n %
Resectable disease
Surgery alone 336 47.7 43 55.1
Surgery  radiotherapy 115 16.3 15 19.2
Radiotherapy alone 116 16.5 12 15.4
Surgery  chemotherapy  radiotherapy 30 4.3 2 2.6
Surgery  chemotherapy 28 4.0 2 2.6
Radiotherapy  chemotherapy 23 3.3 1 1.3
Chemotherapy alone 15 2.1 0 0.0
Supportive care only 41 5.8 3 3.8
Locally advanced disease
Radiotherapy alone 114 40.0 14 53.8
Radiotherapy  chemotherapy 98 34.4 6 23.1
Chemotherapy alone 31 10.9 2 7.7
Chemotherapy  surgery  radiotherapy 12 4.2 1 3.8
Chemotherapy  surgery 2 0.7 0 0.0
Supportive care only 28 9.8 3 11.5
Metastatic disease
Chemotherapy alone 197 43.5 36 45.0
Radiotherapy alone 71 15.7 12 15.0
Radiotherapy  chemotherapy 42 9.3 4 5.0
Chemotherapy  surgery 4 0.9 0 0.0
Surgery 1 0.2 0 0.0
Chemotherapy  radiotherapy  surgery 1 0.2 0 0.0
Supportive care only 142 31.3 28 35.0
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agents was given to 29.6% of males and to 32.5% of females.
Thus, chemotherapy with platin salts was given to 80.2% of
men and to 70.0% of women (p 0.142), with a trend toward
smaller differences between sexes when combined with re-
cent agents.
Independent of the stage of disease, the proportion of
men and women treated by chemotherapy and included in
clinical trials was similar: 11.3 and 13.0%, respectively (p 
0.725).
Simple Regressive Analysis of Relative Survival
Overall survival did not differ significantly according to
the sex of the patients (p  0.840; Figure 2): median survival
time was 9.9 months for the women and 10.5 months for the
men. The 1-, 2-, and 5-year survival rates were, respectively,
45.9, 29.1, and 15.3% in males and 44.9, 30.4, and 17.1% in
females.
Variables that had a significant influence on survival
were histological subtype (p  0.00001), age (p  0.00001),
and stage (p  0.00001). Overall relative survival did not
change significantly during the study period (p  0.861).
Multiple Regressive Analysis of Relative
Survival
A multiple regressive analysis was performed to assess
the influence of sex independent of the effects of the other
variables.
First, we included in the model, in a forward-stepwise
procedure, the pretherapeutic variables: age, histological sub-
type, sex, period, and disease extent (Table 6).
Sex was not a significant prognostic factor (p 0.475),
and no significant interactions were identified between sex
and the other variables. Less favorable prognostic factors
were age 70 years, mixed subtype, advanced disease, bilat-
eral disease, and undetermined stage. On the other hand,
ADOBAC and BAC were more favorable prognostic factors.
In a second analysis, we included in the models the
pretherapeutic and the therapeutic variables: initial treatments
were added to the models. Because treatments are strongly
correlated to the extent of the disease, we performed a
separate analysis for each stage (resectable disease, locally
advanced disease, and metastastic disease). Because of the
very small numbers, bilateral and mixed-histology cancers
were excluded (n 54) from the analyses, as were subgroups
of fewer than 20 patients (n  36).
When treatments were taken into account,12 sex did not
influence survival, and age had no more prognostic value.
Histology was a significant prognostic factor only in meta-
static disease: higher survival rates were observed for patients
with ADOBAC and BAC compared with patients with squa-
mous cell carcinoma.
Among the patients with resectable-stage disease, those
who could be operated on, and, moreover, those operated on
and who received chemotherapy, had the best survival com-
pared with those who could not be operated on. In locally
advanced disease, the best survival was observed for patients
who underwent radiotherapy plus chemotherapy. In meta-
static disease, the lowest survival was observed for patients
with supportive care only or treated with chemotherapy
including older agents without platin.
DISCUSSION
Our patients were extracted from the general popula-
tion, which is not affected by the selection biases linked to
clinical trials. On the other hand, retrospective studies, con-
trary to clinical trials, are subject to missing charts and
missing data. Some differences were noted between the 197
excluded patients (because of missing charts) and the 1738
FIGURE 2. Overall relative survival according to gender.
TABLE 6. Multiple Regressive Analysis of Relative Survival
for Pretherapeutic Variables
Hazard
Ratio
Confidence
Interval p
Sex 0.475
Men 1
Women 0.94 0.79;1.12
Age (yr) 5  105
55 1
56–70 1.05 0.91;1.20
70 1.38 1.18;1.61
Histology 2  103
Squamous cell 1
Adenocarcinomas other than
bronchioloalveolar carcinomas
0.84 0.73;0.97
Bronchioloalveolar carcinomas 0.64 0.47;0.89
Large cell 0.97 0.81;1.17
Mixed 1.76 1.02;3.03
Stage 105
Resectable 1
Locally advanced 2.78 2.39;3.25
Metastatic 5.41 4.71;6.22
Bilateral 2.08 1.45;2.98
Undetermined 6.13 4.56;8.23
Period 0.460
1982–1985 1
1986–1989 0.98 0.83;1.15
1990–1993 0.90 0.76;1.05
1994–1997 0.91 0.78;1.07
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included patients. First, missing charts were more frequent in
women (17.2% versus 9.2% for the men; p  0.0001). We
have no explanation for this. Nevertheless, a similar finding
was observed in a French report about hepatocellular carci-
nomas conducted in the same department15: 15.4% of the
charts were missing in women compared with only 6.9% in
men. Second, the median age was higher in patients with
missing charts, as reported by some authors.16,17 Third, a
significantly lower median survival time was observed in
excluded patients: 5.0 versus 10.5 months. The small size of
the charts of patients who experienced early death may
explain that they are lost more frequently. Missing data were
especially frequent for two variables: performance status,
which was therefore excluded from the analyses; and TNM
stage at diagnosis, which was replaced by a gross clinical
classification into resectable, locally advanced, and meta-
static stage.
Women began smoking on a large scale in France at the
end of the 1960s,18 more than two decades after American
women.19 As a consequence, in 2000, there is a huge differ-
ence between the sex ratio of lung cancer incidence in these
two countries: 6.1/1 in France4 versus 1.7/1 in the United
States.20 The French situation is still far from the U.S. one,
where, since 1987, lung cancer has caused more deaths than
breast cancer among women.21 Comparatively, deaths related
to lung cancer among French women are approximately three
times lower than those related to breast cancer. Nevertheless,
in our study, the sex ratio declined from 10.6/1 in 1982–1985
to 6.7/1 in 1994–1997. Our estimations are very close to
those calculated by the French departmental population-based
cancer registries: the sex ratio estimated for the whole French
population was 12.8/1 in 1980 and 7.4/1 in 1995.4 Thus, it is
to be expected that, within a few years, the incidence and
mortality rates for lung cancer will reach those observed in
North America.
Even if tobacco is the main cause of lung cancer in
females, the attributable risk is lower in females than in
males. For example, worldwide, in 2000, an estimated 85% of
lung cancer cases in men and 47% in women were attributed
to tobacco smoking.22 In Europe, about 70% of lung cancer
in females are attributed to active smoking habits versus
85% in males.23
In our study, 28.9% of women had never smoked
versus 1.4% of the men. This lower percentage of smokers
among women with lung cancer has been reported in many
studies.24–27
Nevertheless, we were not able to assess the exposure
to environmental tobacco smoke in our study. An American
study has reported that 82% of nonsmoking women diag-
nosed with lung cancer had been affected by passive smok-
ing.28 It was established that there is a statistically significant
excessive risk of lung cancer in never-smokers from second-
hand tobacco smoke, estimated at 30%.4
In never-smokers, other risk factors have been reported:
genetic factors,29–30 diet,31–32 previous history of respiratory
disease,33–35 indoor pollution,31,34,36–37 and outdoor pollu-
tion.38–39 Endocrine factors have also been involved in the
carcinogenesis of lung cancer, especially adenocarcinoma.
The presence of estrogen receptors has been demonstrated on
human lung cancer tissue.40 The role of hormonal replace-
ment therapy in menopausal women is still controversial;
some authors have demonstrated that after adjustment for
smoking, the use of estrogen therapy increased the risk of
developing lung adenocarcinoma,41 whereas others did not
find an excessive risk attributable to estrogen therapy.42 In a
very recent study, estrogen therapy was associated both with
lower age at diagnosis and with poorer survival.43 We could
not analyze the frequency of estrogen therapy in our retro-
spective study.
Many studies, mostly case-control studies, suggest that
women have a greater susceptibility to lung cancer than do
men.44–48 Several factors might explain this higher sensitiv-
ity. Capacity of DNA repair is, for example, inferior in
females.49 DNA adducts caused by tobacco smoke are more
frequent in females than in males, whatever the level of
smoking; also, the CYP1A1 (a gene involved in the first phase
of the metabolism of polycyclic aromatic hydrocarbons) level
of expression is higher in females.50 K-Ras mutations are also
more frequent in female smokers than in male smokers.51,52
Also, mutations of K-Ras have been observed in never-
smoking females but not in never-smoking males.53
Data are, nevertheless, conflicting; other studies do not
support this hypothesis.54–58 Two prospective studies are of
particular interest: the first one included 30,874 subjects
between 1964 and 199459; the second, published in 2004,
analyzed two large cohorts and reviewed results from pro-
spective analyses.60 Both conclude that women did not seem
to be at higher risk of development of a lung cancer than men,
given equal smoking exposure.
The mean age at diagnosis did not differ significantly
between women and men (64.7 years versus 63.2 years; p 
0.069). In a Swiss study of patients undergoing surgery for
NSCLC, the proportion of women was higher in the group of
patients who were older than 70 years (p  0.04).25 On the
other hand, various authors have observed that women were
younger than men at diagnosis.24,26
More NSCLC were discovered at the metastastic stage
in women than in men: 41.1% versus 29.9%; this is consistent
with previous reports.26,61–62 On the other hand, other studies
have reported that women were diagnosed at an earlier stage
than men,24 or that they did not detect significant associations
between gender and stage at diagnosis.27,63 The excess of
metastatic-stage disease in French studies may be attributed,
in part, to a delayed diagnosis in women, because of the
relative scarcity of lung cancer and to the predominance of
adenocarcinoma in women. This subtype is usually located in
the periphery of the lung, thus inducing symptoms only at
later stages. Because of this peripheral location, bronchofib-
eroscopy is inefficient in detecting these tumors,64 and in our
study, as well as in others,25,62 bronchial biopsy or brushing
contributed less frequently to the histologic diagnosis in
women. In contrast, fine-needle biopsy, pleural biopsy, and
tap were performed more frequently in women.
In the metastatic stage, women presented pulmonary or
pleural metastases significantly more frequently than did
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men; no significant differences of this type were noted in a
U.S. study.24
In Europe, adenocarcinoma is the most common sub-
type found in women, whereas in men, squamous cell carci-
noma is the most common subtype.2,24,26–27,65 In our study,
adenocarcinoma represented 43.7% of NSCLC in women and
21.0% in men, and squamous cell carcinomas represented,
respectively, 31.5 and 65.9% of cases. In addition, adenocar-
cinoma predominated in never-smoking women, whereas
squamous cell carcinoma was more frequent in smoking
women. The stronger association between squamous cell
carcinomas and tobacco is well known.26–27,66–68 In Europe,
squamous cell carcinoma still remains the most prevalent
subtype, in contrast to the United States, where, since the
middle of the 1980s, adenocarcinomas have represented the
most common subtype.69 The increasing rate of lung cancer
in women in the United States cannot completely explain this
trend, because the proportion of adenocarcinoma is also
rising in men. The reasons of these changes over time are
unclear, but they could be related to the modification of
smoking habits that happened earlier in the United States than
in Europe. For example, cigarettes with filters and blond
tobacco, which are increasingly used, encourage deeper in-
halation; this favors the development of peripheral lung
cancers, which are predominantly adenocarcinomas.69–73
Also, increases in adenocarcinomas are now observed in the
northwest of Europe, in the Netherlands,74 and in Sweden.27
This increase in adenocarcinomas was also observed in our
study in women and in men, particularly during the last
periods. Nevertheless, the trend in histological distribution
could, to some extent, be attributable to detection bias, case
selection, or differences in pathological classification.8,75–76
We did not find disparities in symptoms at diagnosis
according to gender, similar to another study.27 Nevertheless,
we did not separate cough and hemoptysis within the respi-
ratory symptoms. It has been reported that women more
frequently experience cough and that men more frequently
experience hemoptysis.25 Men and women underwent the
same staging procedures, except for the abdominal computed
tomography scan, which was more frequently performed in
women to eliminate a primary cancer of the reproductive
tract. Another study did not observe any differences in pro-
cedures performed at diagnosis, according to sex.77
Management varied in some ways between men and
women. The proportion of lobectomies was greater in women
than in men, whereas more men underwent pneumonectomy
than women. This finding is probably related to the peripheral
location of adenocarcinomas and was also observed in other
studies.25,77 In locally advanced disease, the mean doses of
mediastinal tumor irradiation were significantly lower in
women than in men (48.0 grays versus 55.5 grays). This may
be explained by more prominent toxicity attributable to ra-
diotherapy in females.78 This increased toxicity might have
induced premature stops in radiation therapy more frequently
in females than in males. In the metastatic stages, women
underwent chemotherapy with platin less frequently than did
men (70.0% versus 80.2%), but this difference was not
significant (p  0.142). There were more elderly patients
among women; this could partly explain the tendency to-
wards less cisplatin-based chemotherapy, although the num-
bers are small. We cannot rule out the possibility that a
specific management of female patients might have resulted
in less frequent use of cisplatin. A U.S. study performed
between 1974 and 1998 has shown that a higher proportion of
women underwent surgery and that radiotherapy was more
frequently administered to men than to women.63 Another
report has shown that women were less likely to receive
chemotherapy.79 Other authors did not observe any differ-
ences according to gender in the therapeutic management of
lung cancer patients.62,80
In our study, women with NSCLC did not have a
survival benefit compared with men. The 5-year relative
survival probabilities were 17.1% in women and 15.3% in
men in simple regressive analysis of relative survival. The
rate observed for men is close to the rate estimated in the
United States, according to data collected by the population-
based registries of the Surveillance, Epidemiology, and End
Results program: this rate was 13.6% in 1980–1982 and
15.0% in 1995–2000.81 Conversely, the 5-year survival rate
estimated for women in the Surveillance, Epidemiology, and
End Results database is slightly higher than ours81: 18.4% in
1980–1982 and 19.2% in 1995–2000. Sex was not an inde-
pendent determinant of survival in our study, as was the case
in another French study performed between 1982 and 1991
that included 1551 cases of NSCLC registered in a university
hospital.82 Nevertheless, many studies, mainly from North
America, have demonstrated a survival advantage for women
in NSCLC.9,10,24–26,65,77,83 The very low proportion of women
in NSCLC patients in France—11% in our study (n  197),
and 9% in the Moro’s study (n 146)82—may result in a lack
of power to detect a difference in survival.
CONCLUSION
This study confirms known sex differences in presen-
tation (stage, histological subtype), smoking exposure, and
management, but not in survival. This last finding is possibly
attributable to a lack of power; the proportion and the number
of female patients are small compared with those of most
North American studies, where women seem to have longer
survival rates. Our retrospective study underscores the need
to determine whether the gender specificities are related to
true differences between genders (i.e., genetic, hormonal,
higher sensitivity to carcinogens) or to different kinds and
levels of exposure to carcinogens (smoking and diet habits,
occupational exposure).
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